Molecular staging of gynecological cancer: What is the future?

Pratibha S. Binder; Jaime Prat; David G. Mutch

doi:10.1016/j.bpobgyn.2015.01.008

Molecular staging of gynecological cancer: What is the future?

Pratibha S. Binder, Jaime Prat, David G. Mutch

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The purpose of cancer staging is to classify cancers into prognostic groups and to allow for comparison of treatment results and survival between patients and institutions. Staging for gynecologic cancers is based on extent of disease and metastasis, which was historically determined by physical examination and is now based on surgical and histologic examination of tumor specimens. Although the extent of disease is currently considered the most important predictor of recurrence and survival, current staging does not include molecular features that are associated with tumor aggressiveness, response to therapy, and prognosis. This review focuses on genomic and proteomic features of gynecologic cancers and the future of biomarkers in staging classification.

Original language	English
Article number	1469
Pages (from-to)	776-789
Number of pages	14
Journal	Best Practice and Research: Clinical Obstetrics and Gynaecology
Volume	29
Issue number	6
DOIs	https://doi.org/10.1016/j.bpobgyn.2015.01.008
State	Published - Aug 1 2015

Keywords

biomarker
gynecologic cancer
molecular classification
prognosis
staging

Access to Document

10.1016/j.bpobgyn.2015.01.008

Cite this

@article{f35b1f63ebea414b9c614646a818ed7f,

title = "Molecular staging of gynecological cancer: What is the future?",

abstract = "The purpose of cancer staging is to classify cancers into prognostic groups and to allow for comparison of treatment results and survival between patients and institutions. Staging for gynecologic cancers is based on extent of disease and metastasis, which was historically determined by physical examination and is now based on surgical and histologic examination of tumor specimens. Although the extent of disease is currently considered the most important predictor of recurrence and survival, current staging does not include molecular features that are associated with tumor aggressiveness, response to therapy, and prognosis. This review focuses on genomic and proteomic features of gynecologic cancers and the future of biomarkers in staging classification.",

keywords = "biomarker, gynecologic cancer, molecular classification, prognosis, staging",

author = "Binder, {Pratibha S.} and Jaime Prat and Mutch, {David G.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd.",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/j.bpobgyn.2015.01.008",

language = "English",

volume = "29",

pages = "776--789",

journal = "Best Practice and Research: Clinical Obstetrics and Gynaecology",

issn = "1521-6934",

number = "6",

}

TY - JOUR

T1 - Molecular staging of gynecological cancer

T2 - What is the future?

AU - Binder, Pratibha S.

AU - Prat, Jaime

AU - Mutch, David G.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The purpose of cancer staging is to classify cancers into prognostic groups and to allow for comparison of treatment results and survival between patients and institutions. Staging for gynecologic cancers is based on extent of disease and metastasis, which was historically determined by physical examination and is now based on surgical and histologic examination of tumor specimens. Although the extent of disease is currently considered the most important predictor of recurrence and survival, current staging does not include molecular features that are associated with tumor aggressiveness, response to therapy, and prognosis. This review focuses on genomic and proteomic features of gynecologic cancers and the future of biomarkers in staging classification.

AB - The purpose of cancer staging is to classify cancers into prognostic groups and to allow for comparison of treatment results and survival between patients and institutions. Staging for gynecologic cancers is based on extent of disease and metastasis, which was historically determined by physical examination and is now based on surgical and histologic examination of tumor specimens. Although the extent of disease is currently considered the most important predictor of recurrence and survival, current staging does not include molecular features that are associated with tumor aggressiveness, response to therapy, and prognosis. This review focuses on genomic and proteomic features of gynecologic cancers and the future of biomarkers in staging classification.

KW - biomarker

KW - gynecologic cancer

KW - molecular classification

KW - prognosis

KW - staging

UR - http://www.scopus.com/inward/record.url?scp=84938748175&partnerID=8YFLogxK

U2 - 10.1016/j.bpobgyn.2015.01.008

DO - 10.1016/j.bpobgyn.2015.01.008

M3 - Article

C2 - 25934522

AN - SCOPUS:84938748175

SN - 1521-6934

VL - 29

SP - 776

EP - 789

JO - Best Practice and Research: Clinical Obstetrics and Gynaecology

JF - Best Practice and Research: Clinical Obstetrics and Gynaecology

IS - 6

M1 - 1469

ER -

Molecular staging of gynecological cancer: What is the future?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this